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Abstract
H. pylori drug-resistant strains and non-compliance to therapy are the major causes of H. pylori eradication failure. For some
bacterial species it has been demonstrated that fatty acids have a growth inhibitory effect. Our main aim was to assess the
ability of docosahexaenoic acid (DHA) to inhibit H. pylori growth both in vitro and in a mouse model. The effectiveness of
standard therapy (ST) in combination with DHA on H. pylori eradication and recurrence prevention success was also
investigated. The effects of DHA on H. pylori growth were analyzed in an in vitro dose-response study and n in vivo model.
We analized the ability of H. pylori to colonize mice gastric mucosa following DHA, ST or a combination of both treatments.
Our data demonstrate that DHA decreases H. pylori growth in vitro in a dose-dependent manner. Furthermore, DHA inhibits
H. pylori gastric colonization in vivo as well as decreases mouse gastric mucosa inflammation. Addition of DHA to ST was
also associated with lower H. pylori infection recurrence in the mouse model. In conclusion, DHA is an inhibitor of H. pylori
growth and its ability to colonize mouse stomach. DHA treatment is also associated with a lower recurrence of H. pylori
infection in combination with ST. These observations pave the way to consider DHA as an adjunct agent in H. pylori
eradication treatment.
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Introduction
Helicobacter pylori infection is extremely common world-wide with
more than two thirds of the world population infected. This gram-
negative bacterium is recognized as a major etiological factor in
chronic active gastritis, gastric duodenal ulcers and gastric cancer.
Successful treatment of this pathogen often leads to regression of
some of its associated diseases [1]. The outcome of the infection
depends on the complex interaction established between the
bacteria and its host, including the virulence of the infecting strain
and the genetic factors and age of the host. Environmental factors,
mainly associated to diet, also contribute to this complex interplay
[2].
H. pylori eradication treatment has not changed to a large extent
in the last decades. It relies on a triple therapy approach that
combines clarithromycin or metronidazole in combination with
other antibiotics and acid inhibitors [3]. However, this treatment
regimen raises some concern mainly due to possible recurrence of
infection, high cost, side effects, poor compliance to therapy and
most importantly, acquired resistance to classically used antibiotics
[4–8]. In fact, it has been estimated that eradication therapy is
unsuccessful in approximately one in every five patients [4,6,8–9].
Therefore a proper regimen should have high efficacy against
clarithromycin and metronidazole-resistant strains of H. pylori
because these strains are increasingly encountered in routine
clinical practice.
It has been proposed that certain polyunsaturated fatty acids
(PUFA) hold an inhibitory effect on bacterial growth [10–15].
Some mechanisms have been reported for PUFAs bacteria
inhibitory action and gastric protective effect. These include the
ability to disrupt cell membrane leading to bacteria lysis [15], and
the ability to modulate the synthesis of mucosal anti-inflammatory
prostaglandins, such as Prostaglandin E2 (PGE2) [16]. The decline
in duodenal ulcer incidence associated with the rise in dietary
intake of PUFA, independently of H. pylori treatment, led to a
growing interest in the role of these fatty acids [17]. Furthermore,
it has been demonstrated that concentration of 2.561024 M of
Linoleic acid (n-6 PUFA) could inhibit the growth of H. pylori in
vitro. This inhibitory effect is thought to be related to the extent of
unsaturation within PUFA [10]. Despite the documented anti-
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microbial effect of PUFAs on the growth of fungi, protozoan,
viruses and various types of bacteria [3,18], few studies have
described their action on H. pylori growth and viability.
To our knowledge, no studies have investigated the effects of
docosahexaenoic acid (DHA), a highly unsaturated PUFA present
in fish oil, on H. pylori growth in vitro and most importantly in vivo
on its ability to colonize gastric mucosa. Our general aim was
therefore to assess the effect of DHA on H. pylori growth using both
in vitro and in vivo models. We performed an in vitro dose-response
study of H. pylori growth inhibition by DHA, as well as an analysis
of DHA effectiveness in inhibiting H. pylori gastric mucosal
colonization in a mouse model. We also compared the
effectiveness of a standard therapy (ST) combined with DHA in
H. pylori eradication and recurrence success.
Methods
Fatty acids, H. pylori strains and culture conditions
DHA was obtained from Cayman Chemical Company (Michigan,
USA) with a degree of purity of 99% in ethanol 0.06%. The H.
pylori strains used were: SS1 [19], B128 [20] and 26695 (ATCC
700392) obtained from the American Type Culture Collection
(ATCC, Rockville, MD). H. pylori was grown on blood agar base 2
(Oxoid, Lyon, France) plates supplemented with 10% defibrinated
horse blood (bioMe´rieux, Marcy l’Etoile, France). Plates were
incubated at 37uC for 24 to 48 h under microaerobic conditions
(7% O2, 10% CO2; Campygen gas pack; Oxoid). To determine
growth kinetics, plate-grown H. pylori strains were inoculated to an
initial optical density at 600 nm (OD600) of 0.03 into liquid
Brucella broth (BB) (Oxoid) supplemented with 10% fetal calf
serum (FCS).
H. pylori grown for 18–20 hours yield a viable count of
approximately 5.646108 colony forming units (CFU)/ml.
DHA treatment of H. pylori cultures
Stock solutions of DHA were diluted in BB enriched with 10%
FCS and used from 50 mM to 1000 mM. To establish H. pylori
growth curves, 18–20 hours bacteria cultures were diluted 100-
fold in 10 ml of medium with or without DHA to an initial OD of
0.03. Each experiment, consisting of a control (non-treated H.
pylori culture) and H. pylori incubated with DHA at 50 mM,
100 mM, 250 mM, 500 mM and 1000 mM was performed in
triplicate. H. pylori broth cultures were incubated under micro-
aerophilic conditions, as described above. Every 6 hours, during a
48 hours period, a 200 mL sample of each bacterial culture was
isolated, the OD measured and aliquots serially diluted and plated
on blood agar petri dishes. After 48 hours of incubation, the
number of viable bacteria was determined by colonies forming
unit (CFU) counting.
The ID50 values were determined for the three strains every
12 hours until 72 hours of growth in the presence of increasing
concentrations of DHA from 50 to 1000 mM. ID50 corresponds to
the DHA dose that leads to 50% of bacteria survival characterized
by the ratio between the number of viable bacteria at a certain
dose of DHA compared to the number of total bacteria in the
control culture at the same time-point.
Electron microscopy analysis
In order to examine the effect of DHA treatment on H. pylori
structure and morphology, strains 26695 and SS1 were grown for
12 hours in the presence of DHA 100 mM, as described. Then,
control and DHA treated H. pylori cultures were observed by
scanning electron microscopy. Briefly, samples were washed in
phosphate buffered saline (PBS) and fixed in 2.5% glutaraldehyde
for 30 min. Fixed bacteria were dehydrated in ethanol and treated
with hydroxymethyl disilazane dried over a glass coverslip and
sputter-coated with gold-palladium. The resulting samples were
examined with a FEG-SEM JEOL 7001F electron microscope.
Mouse infection and DHA treatments
Mouse infection studies were carried out in strict accordance
with the recommendations in the Specific Guide for the Care and
the Use of Laboratory Animals of the Institut Pasteur, according to
the European Directive (2010/63/UE) and the corresponding
French law on animal experimentation (Arreˆte´s de 1988). The
protocol used in the present study was approved by the Committee
of Central Animal Facility Board.
Six-week-old specific pathogen-free (H. pylori free) C57BL/6
male mice (Charles Rivers, France) were orogastrically inoculated
with 100 mL of a suspension of 108 CFU/mL of H. pylori strain
SS1 known to colonize efficiently the mouse gastric mucosa,
whereas control groups of mice were given peptone trypsin broth
alone. This is a well-established mouse model of H. pylori infection
[21–22]. The experiment consisted of four groups of twenty-four
mice. Each group was further divided into four groups of six mice:
control group (given peptone trypsin broth alone), non-infected
DHA-treated group, H. pylori infected group and H. pylori infected
and DHA-treated group. Mice from DHA treated groups received
drinking water supplemented with 50 mM of DHA, 24 hours after
H. pylori SS1 infection and throughout the entire experiment. The
DHA concentration used was determined according to the notion
that the maximum daily recommendation for total n-3 PUFA in
humans, is between 1–2 g/day (50 to 100 mM in the gastric
milieu). To prevent any degradation of DHA due to light, the
supplemented drinking water was contained in dark-coloured
bottles. Toxicity signs associated to DHA treatment in mice were
checked during the experiment (weight variation, appetite and
liver-gastric histopathology). No toxic effects were observed: no
weight variations (Figure S1) and no signs of liver toxicity as
indicated by histopathology analysis (data not shown). At each
time-point (one, three, six and nine months) six mice from each
group were sacrificed, stomachs isolated and H. pylori colonisation
measured as previously described [22]. Since H. pylori is a human-
specific bacteria that is not able to colonize the mouse stomach
unless inoculated, no animals were sacrificed at the time-point
zero. The number of viable bacterial colonies was counted and
expressed as CFU per gram of gastric tissue.
Mouse DHA and Antibiotics standard therapy treatment
(ST)
The efficacy to eradicate H. pylori infection in mouse gastric
mucosa was compared between a 7-days ST associated or not with
a 15-days treatment of DHA 100 mM. This concentration of DHA
was used in order to allow as much as possible DHA saturation in
the mouse gastric lumen. No toxic side effects were observed in
this condition of DHA treatment. The efficacy in preventing H.
pylori recurrence following ST and/or DHA treatment regimen
was also assessed prospectively (time-point 14 weeks). Twenty-four
mice were infected by H. pylori strain SS1 for 4 weeks and divided
into four groups of six animals. An additional group of non-
infected and non-treated animals (n = 4) was given peptone trypsin
broth alone as a control. Briefly, infected mice were dosed p.o. with
omeprazole (400 mmol/kg/d; Sigma-Aldrich), metronidazole
(14.2 mg/kg/d; Sigma-Aldrich), and clarithromycin (7.15 mg/
kg/d) in a 0.1-ml volume daily for 7 days [23]. This antimicrobial
regimen previously showed 100% eradication of H. pylori in
C57BL/6 infected mice and it is referred to as ST [23]. Three
therapeutic options were analyzed: ST p.o. for 7 days, DHA
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addition to drinking day water for 15 days, or a combination of
both ST for 7 days, and at the same time DHA for 15 days. All
treatments were administered at 4 weeks post-H. pylori infection.
Mice were euthanized at 6 and 14 weeks post- infection; stomachs
were isolated and H. pylori colonization was quantified as
previously described [22].
Mouse gastric histology
After 6 and 9 months of infection, mice stomachs were subjected
to histology analysis. Biopsy specimens were fixed in 10% formalin
routinely processed in paraffin. Four-mm sections were stained
with hematoxylin/eosin. Gastric histology analysis was assessed for
both antrum and corpus parts. The intensity of the lesions was semi-
quantitatively classified according to Eaton et al [24]. Briefly,
infiltrates of polymorphonuclear cells (PMN) and plasmocytes
were graded as follows: 0 – no infiltrates; 1 – mild, multifocal
infiltration; 2 – mild, widespread infiltration; 3 – mild, widespread
and moderate multifocal infiltration; 4 – moderate widespread
infiltration; 5 – moderate, widespread and severe multifocal
infiltrations. Lymphoid (Linf) aggregates were graded 1 (mild, 1–
10 glands), 2 (moderate, 10 to 20 glands) or 3 (severe, more than
20 glands).
Measurement of prostaglandin-E2 (PGE2) in mouse
serum
At each time-point of sacrifice (one, three, six and nine months)
mice serum was collected and kept at 220uC, until further
analysis. PGE2 levels were determined by enzyme immunoassay
using a Prostaglandin-E2-Monoclonal Enzyme immunoassay Kit
(R&D systems, Minneapolis, USA) according to the manufactur-
er’s protocol.
Statistical Analysis
Statistical analysis were performed with the R software [25]
Data on the effects of DHA on H. pylori growth in vitro were
analysed with a linear model using the ‘‘lm’’ function and default
settings. For each strain the linear model included only the dose as
qualitative variable. Then pairwise t-tests were performed to assess
the significance of differences between doses, with a Hochberg p-
value adjustment for multiple testing [26]
Results in mice experiments are expressed by median values as
the data do not follow a normal distribution. Pairwise comparison
Mann-Whitney U tests were used to assess differences in mouse
gastric colonization by H. pylori when supplemented with DHA
with a Hochberg P-value adjustment for multiple testing [26].
Kruskal-Wallis test was used to assess decreasing H. pylori
recurrence rate with DHA addition to ST. All statistical tests
were two-sided. Differences were considered significant for
P,0.05. To assess the significance of anti-inflammatory effect of
DHA in the infected gastric mucosa of mice, a student t-test was
performed to compare control condition vs treated condition for
each combination of time and stomach region considered. The
four resulting p-values were then adjusted with the Hochberg
method [26]. To analyze the differences in PGE2 production in
infected mice treated with DHA compared to untreated, a linear
model was fitted to the data including time and treatment as
qualitative variables, as well as the interaction term.
Results
H. pylori growth is inhibited by DHA in vitro
In order to analyse DHA effects on H. pylori growth, three
different bacterial strains 26695, SS1 and B128 were studied
(Figure 1). H. pylori growth in controls was exponential until
approximately 18–20 hours, then reaching a stationary phase. In
the presence of DHA, the growth of these three strains was
reduced with a statistically significant effect from DHA 100 mM
(P=2.86610211; P=1.37610208; P=9.64610212 for strains
26695, SS1 and B128 respectively). In addition, the statistical
analysis of DHA effect between the different doses by pair-wise t-
test showed a significant difference between bacterial growth
observed at DHA 50 mM compared to the highest inhibitory doses
of DHA from 100 mM to 1000 mM (461027,P,6.461026).
Generation time during exponential growth phase (0–18 h) was
longer for 100 mM of DHA in all strains compared to controls
(P,0.05). At higher concentrations of DHA (250 mM or more) the
effect on bacterial cultures was drastic with no growth observed for
all strains, compared to control (P=9.41610212; P=1.36610208;
P=2.30610212 at DHA 250 mM, for strains 26695, SS1 and
B128 respectively) (Figure 1).
The concentration required to inhibit growth of bacteria by
50% (ID50) at 48 hours of culture was 75 mM for both H. pylori
strains 26695 and B128, and 85 mM for strain SS1 (Figure S1).
The efficiency of DHA to inhibit H. pylori growth in vitro was
therefore similar for all strains.
Scanning electron microscopy was used to analyse the
morphology of H. pylori strains 26695 and SS1 following DHA
treatment. After being treated with 100 mM of DHA, strains
26695 (figure 2A) and SS1 (figure 2B) showed a different
morphology when compared to controls, as characterized by the
presence of spherical/coccoid forms. Treatment with 250 mM
DHA had a dramatic effect on the morphology of the few
moribund bacteria present in the culture (data not shown). Thus,
DHA is an efficient inhibitor of H. pylori growth in vitro, promoting
the coccoid morphology of bacteria that is known to be a non-
cultivable form [27].
DHA inhibits H. pylori gastric colonization in mice
In order to assess the effectiveness of DHA as a therapeutic
agent, we investigated the effect of exposure to DHA on the H.
pylori colonization of mouse gastric mucosa. The ability of H. pylori
strain SS1 to colonize the gastric mucosa was significantly
decreased in 50 mM DHA-treated mice as compared to mice
from the infected non-treated group at each time-point of infection
from 1 to 9 months (P values: 0.028; 0.023; 0.024 and 0.020 at 1,
3, 6 and 9 months respectively) (Figure 3A). In the non-treated
group, all animals were successfully colonized by H. pylori. In
contrast, amongst DHA supplemented-mice, only 50% of animals
are infected, with a median value for the gastric colonization lower
than 3 to 4 Log compared to the infected and non DHA-treated
group at the same time-point. No toxic effects were observed due
to DHA treatment: no weight variations (Figure S2) and no signs
of liver toxicity as indicated by histopathology analysis (data not
shown). These data showed that also in vivo, DHA inhibits
efficiently H. pylori gastric colonization.
DHA and ST treatments
It has already been shown that triple therapy consisting of
omeprazole plus two antibiotics (clarithromycin and metronida-
zole) is 100% efficient in eradicating H. pylori in the mouse gastric
mucosa [23]. We confirmed ST 100% efficacy in our mouse
model: no colonization in the group of mice treated with ST at the
6 weeks time-point (P=0.01) which corresponds to one week after
the end of ST treatment (Figure 3B). It is known that subsequently
to the antibiotic treatment against H. pylori infection there is a
significant percentage of relapses. Therefore, our aim was to
compare prospectively the rate of H. pylori infection recurrence
between ST and ST+DHA treatment regimens. Mouse gastric
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colonization was compared after ST, DHA or ST+DHA
treatments at the time-points 6 and 14-weeks that correspond to
4 weeks of infection followed by 2 and 10 weeks after the end of
treatment, respectively. At the time-point 6 weeks, although not
reaching statistical significance, a decrease in the gastric
colonization is observed in DHA treated mice. As previously
mentioned ST was 100% efficient in inhibiting colonization
(Figure 3B), with none of the infected mice presenting H. pylori
viable colonies in the gastric mucosa. At 14-weeks the presence of
DHA had a significant inhibitory effect on the H. pylori infection
recurrence, whether used alone (P=0.04) or as an adjuvant to ST
(P=0.0028), as compared to infected mice untreated (Figure 3B).
Among the six mice receiving ST+DHA at 14 weeks post
infection, none showed viable H. pylori in their gastric mucosa,
Figure 1. DHA effect on H. pylori growth. Growth of H. pylori strains A) 26695, B) SS1 and C) B128 during 48 hours in the presence of increasing
concentrations of DHA from 50 to 1000 mM. Ethanol 0.06% v/v was used as a vehicle in DHA original stock solution, and therefore the presence of
ethanol at the same concentration was also analyzed on H. pylori control culture with no effect on bacterial growth for the three strains. Data are
expressed as the mean 6 Standard Deviation and are representative of three independent experiments. * Refers to significant differences in H. pylori
growth between controls and DHA-treated conditions (50 mM to 1000 mM of DHA).
doi:10.1371/journal.pone.0035072.g001
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compared to 1 among 5 (20%) and 3 among 6 (50%) (Median
level: 4.56106 CFU/g; SD 4.1) mice in the group treated with ST
and DHA alone, respectively (Figure 3C). At this time-point the
median value of gastric colonization level in non-treated H. pylori
infected mice was 1.76106 CFU/g. These data showed that a
combination of ST plus DHA is very efficient to prevent H. pylori
infection recurrence.
Mouse gastric mucosa inflammation status
Mouse gastric mucosa at 1 and 3 months of H. pylori infection,
did not present significant signs of inflammation. However, at 6
and 9 months post-infection, the gastric mucosa of infected-mice
present important inflammatory lesions with infiltrates of poly-
morphonuclear cells (PMN) and plasmocytes as well as the
presence of important lymphocytes aggregates (Figure 4A). Gastric
inflammation and histology analysis revealed a significant lower
inflammation in the gastric mucosa of H. pylori infected mice
treated with DHA, compared to H. pylori infected mice non-
treated after both 6 (P=1.8361026) and 9 months (P=0.0004) of
infection (Figure 4B). In addition, according to the semi-
quantitative evaluation of inflammatory lesions [24], infiltrates of
PMN, plasmocytes and lymphoid aggregates were less abundant in
DHA-treated mice than in non-DHA-treated ones (P,0.05)
(Figure 4B). These differences were significant at 6 and 9 months
in both parts of the stomach, the antrum (P=1.4761024 and
P=1.461023) and the corpus (P=1.3461023 and P=0.0485),
respectively.
PGE2 is produced in several pathological conditions by a wide
variety of tissues. Increased amount of PGE2 is associated with
inflammation and tissue injury [28]. At both time-points, infected
mice treated with DHA showed lower serum PGE2 levels
compared with infected but non DHA-treated mice (P=0.0284)
(Figure 4C). Altogether, these data showed that in the mouse
model of chronic H. pylori infection, DHA addition is accompanied
by a reduction in the inflammatory response.
Discussion
The present study identifies DHA as a novel antibacterial agent,
which inhibits H. pylori growth in vitro and its ability to colonize the
gastric mucosa in a mouse model. It was previously demonstrated
that some free fatty acids can inhibit up to 50% of H. pylori growth
in vitro within a concentration of 1 mM [13], whereas 2 mM would
kill all bacteria [13,15]. To our knowledge this is the first study
demonstrating the inhibitory effect of DHA on H. pylori growth,
both in vitro and most importantly in vivo. As we showed, DHA is
able to inhibit H. pylori gastric colonization in a significant
proportion of mice (50%, P,0.05). The lack of effect in all DHA-
treated mice may be due to variation in the delivery of DHA to
animals. However, biological variability within mouse population
cannot be excluded. According to these data, DHA treatment
should not be regarded as a replacement strategy for conventional
antibiotic treatment. However, it is very interesting that in an
experiment designed to evaluate DHA effectiveness as a co-
adjuvant to ST antibiotherapy to prevent H. pylori infection
recurrence, the addition of DHA yielded better results than ST
alone. Thus, our results support the use of DHA in combination
with standard antibiotic therapy for H. pylori treatment to inhibit
efficiently the infection recurrence. These data suggests DHA
supplementation as a safe prophylactic/preventive strategy for H.
pylori infection eradication that is worth further consideration.
DHA concentration was a critical point in our study, as the
concentration observed to be effective varied according to the
experimental model used. In in vitro studies, differences in the level
of sensitivity to DHA are observed between the three H. pylori
strains tested. This may be due to the high genetic variability
which characterizes H. pylori strains. Despite that, 100 mM of DHA
is enough to significantly inhibit bacteria growth, with a maximum
inhibitory effect at 250 mM. Hence, DHA concentrations have to
be optimized for different experimental settings in order to obtain
optimum effects. This is not surprising and it is actually typical of
experiments aiming at measuring the effect of different drugs on
microbiological agents [29]. In vivo, several parameters such as the
biodistribution of the compounds, their chemical stability, their
metabolization and their resistance to the extreme acidic
conditions of the gastric lumen can modulate their bioactivity.
Our in vivo analysis showed that the presence of DHA at a
concentration of 50 mM in mice drinking water is efficient to
inhibit significantly H. pylori gastric colonization. This concentra-
tion is within the range of concentrations reachable with diet in the
human stomach for any PUFA [15]. Levels of DHA given to mice
in our experiments are also within a safe and well tolerated range
of concentrations with no toxic effects observed, in agreement with
several clinical trials that have used DHA supplementation at
higher doses with no reports of toxicological effects [30–31].
Despite the experimental data supporting an inhibitory effect of
DHA on H. pylori growth, no association between DHA intake and
H. pylori infection incidence has been made. In fact, it could be
regarded as puzzling that countries like Japan and Portugal, with
dietary habits including high intakes of fat fish naturally rich in
DHA, exhibit some of the highest incidences of H. pylori infection
worldwide. There are several explanations for this apparent
discrepancy: 1- DHA daily intake recommendations in grams do
not have a direct translation in terms of DHA gastric
concentration. It is therefore not guaranteed that a DHA
Figure 2. Alteration of H. pylori morphology upon DHA
treatment. H. pylori strains A) 26695 and B) SS1 cultured for 12 hours
incubated with 100 mM of DHA show changes in cell shape as observed
by scanning electron microscopy. The presence of 100 mM of DHA leads
to spherical/coccoids bacterial forms for both strains.
doi:10.1371/journal.pone.0035072.g002
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Figure 3. Inhibition of H. pylori SS1 gastric colonization by DHA treatment and a combination of standard antibiotherapy (ST) and
DHA in C57BL/6 mice. A) Analysis of H. pylori SS1 gastric colonization inhibition by DHA treatment in C57BL/6 mouse over time. Four groups each
encompassing six mice: one group of non-treated, non-infected controls; one group of animals infected by H. pylori strain SS1; one group of mice
supplemented with 50 mM of DHA in the drinking water; and one group infected by H. pylori strain SS1 and supplemented with 50 mM of DHA in the
drinking water as described in materials and methods. The non-infected control group and DHA treated mice are not colonized and are not reported
in the figure. In each condition mice were sacrificed after one, three, six and nine months. Median values of gastric colonization between H. pylori
infected mice non-DHA treated and DHA treated were 18.366105 vs 0.00496105, 8.246105 vs 0.0696105, 15.716105 vs 0.00966105 and 27.456105 vs
0.0346105 cfu/g of gastric tissue after 1, 3, 6 and 9 months, respectively. * P,0.05; **P,0.005. B) Analysis of the effect of the Standard antibiotics
Therapy (ST) on the level of gastric mucosa colonization by H. pylori infection compared with DHA treatment and DHA in combination with ST in
mice. Four groups of mice, each encompassing six (n = 6) were infected by H. pylori strain SS1. Control group (n = 4) was given peptone trypsin broth
alone. As described in materials and methods, three therapeutic options were given to mice: ST p.o. for 7 days, DHA addition to mice drinking day
water for 15 days, or a combination of both ST for 7 days, and at the same time DHA for 15 days. All treatments were administered at 4 weeks post H.
pylori infection and gastric colonization measured at 6 and 14 weeks post infection. * P,0.05; **P,0.01. C) Number of mice colonized and not
colonized by H. pylori under the different conditions of treatment described above. Open bars represent the number of mice infected by H. pylori
(Hp+), whereas grey bars represent the number of non-infected mice (Hp2). The Kruskal-Wallis test was used to assess the consequences on H. pylori
mouse gastric colonization of DHA treatment. Our results show a significant (P= 0.0036) reduced rate of recurrence of H. pylori infection in animals
supplemented with DHA.
doi:10.1371/journal.pone.0035072.g003
Figure 4. Anti-inflammatory effects of DHA in the infected gastric mucosa of mice. A) Histological analysis of inflammatory lesions of the
gastric mucosa of H. pylori infected or non-infected mice treated or not with DHA 50 mM after 6 and 9 months. No differences were observed
between non-infected mice DHA-treated or non-treated. In infected mice, the DHA treatment in infected mice leads to a decrease of the gastric
mucosa thickness compared to H. pylori infected mice but non-DHA treated at both time-points. Infiltrates of polymorphonuclear (PMN) cells and
plasmocytes as well as number of lymphoid aggregates (arrows) were lower in H. pylori infected mice treated with DHA compared to infected mice
non-treated. The infection leads to the formation of lymphoid aggregate (arrows) not observed in mice treated with DHA. Scale bars correspond to
100 mm. B) Semi-quantification of inflammation score grading in the gastric mucosa. At each time-point, 6 and 9 months, mean score grading for
each group of mice are higher in the antrum than fundus part. The presence of DHA leads to a significant decrease of the antrum inflammation of the
H. pylori infected gastric mucosa. PMN: Polymorphonuclear cells; Linf: Lymphocytes aggregates; Submuc: Submucosa. Comparison was made
between infected mice non-DHA supplemented and infected mice DHA supplemented. C) Measurement of PGE2 in the mice serum. Lower PGE2
values were observed in infected mice that received DHA 50 mM compared to infected mice non-DHA treated (adjusted P values 0.016 at 1 month;
0.008 at 3 months; 0.054 at 6 months; 0.012 at 9 months). PGE2 levels were lower at 6 months in DHA-treated mice compared to untreated mice, even
though the difference cannot be considered statistically significant. Control group corresponds to non-infected and non-DHA treated mice. Bars
represent means with standard deviation.
doi:10.1371/journal.pone.0035072.g004
Docosahexaenoic Acid Inhibits H. pylori Growth
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35072
concentration of 50 mM will be achieved by food consumption,
even when daily intake recommendations are met; 2- DHA is
typically present in food as triacylglycerol that will be hydrolysed
along the digestive tract, leading to only a small amount being
released as free fatty acid in the gastric milieu [32]; 3- the high
degree of unsaturation of the DHA molecule makes it vulnerable
to oxidation and temperature. This can result in the modification
of the DHA chemical structure, and interfere with its anti-
Helicobacter properties. Hence, the level of fish consumption, or any
other DHA-rich food for that matter, does not constitute an
adequate measure of DHA gastric concentration and DHA
availability to H. pylori. This point is well illustrated by the fact
that although no association between fish intake and gastric cancer
risk could be drawn from the Japanese population, the percentage
of DHA in the membrane composition of erythrocytes was directly
associated with a lower risk of developing gastric cancer [33].
These arguments may justify the lack of a positive association
between H. pylori gastric colonization/gastritis and high levels of
PUFA supplementation in clinical trials. As an example is a study
in which H. pylori infected-patients were supplemented with
capsules containing linolenic acid (n-3 PUFA), linoleic acid (n-6
PUFA) or subjected to an increased margarine intake in the diet
[30]. Although PUFA overall levels were significantly increased in
individuals supplemented with PUFAs in comparison with the
control group, no H. pylori growth inhibition or lower inflamma-
tion status were observed.
The mechanism underlying the inhibitory effect of lipids on H.
pylori growth is unknown. However, it has been shown that fatty
acids, in concentrations ranging from 1 to 10 mM, affect the lipid
constitution of the bacterial plasma membrane [18]. A possible
explanation for the bactericidal effect of PUFA relies on the
formation of toxic lipid peroxides generated from an oxidative
process involving H2O2 and iron [10,12]. Another potential
mechanism suggested for the killing of bacteria after exposure to
fatty acids is by cell membrane alteration, leaving the bacterial cell
wall intact. According to this mechanism, fatty acids would be
incorporated into the cell membrane resulting in an increased
membrane fluidity and permeability; this effect would be further
exacerbated by the presence of unsaturated double bounds, as they
seem to exert a toxic effect towards the bacterial cell membrane
[10–15]. Supporting this cell membrane disruption hypothesis, it
has been demonstrated that radiolabeled PUFAs added to H. pylori
liquid cultures are incorporated into the H. pylori plasma
membrane [15]. In agreement, our electron microscopy observa-
tions revealed H. pylori morphological changes upon n-3 PUFA
DHA (C22:6) treatment. A proportion of H. pylori -DHA treated
bacteria displayed coccoid forms, known to be associated with a
bacterial decreased viability [27]. The morphological transition of
H. pylori from a bacillary to a coccoid shape has been previously
reported to be related to modification of the bacterial cell wall
peptidoglycan [34].
In summary, our results show that DHA inhibits H. pylori
growth both in vitro and in vivo. Although the mechanisms
underlying this inhibitory effect are still unclear, our results
demonstrate that DHA impairs H. pylori growth and gastric
colonization and attenuates the host inflammatory response. More
importantly, the combination of DHA and ST strongly decreased
the recurrence of H. pylori infection in the mouse model. Although
not evaluated in this study, the effectiveness of ST/DHA
combined treatment in inhibiting H. pylori-induced gastric
inflammation is another important aspect of the benefit of DHA
therapy that deserves to be further addressed. It should be
emphasized that DHA raises low toxicological constraints and it is
also well tolerated. In agreement, it is widely and commonly used
both at a clinical trial and at a diet level for long time periods.
Additionally, DHA has cytoprotective properties and enhances the
formation of prostaglandins [19].
Although the established therapeutical regimens for H. pylori
eradication have been proven effective, treatment failure still
occurs and is increasingly common [3]. Altogether the data
obtained in the current work may pave the way to propose the use
of DHA in preventive and curative strategies for H. pylori
eradication, as a co-adjuvant agent in combination with standard
therapy. Consequently, DHA supplementation within the range of
concentrations we have tested should be considered as a safe
prophylactic/preventive strategy against H. pylori infection.
Supporting Information
Figure S1 Growth of H. pylori strains 26695, SS1 and
B128 during 72 hours in the presence of increasing
concentrations of DHA from 50 to 1000 mM. Data are
expressed as H. pylori viability upon DHA treatment reported for
bacterial cultures sampled every 12 hours. The number of total
viable bacteria in the control cultures corresponded to 100%
survival.
(DOCX)
Figure S2 Mice weight variation during H. pylori
infection and DHA treatment. Four groups each encompass-
ing six mice: one group of non-treated, non-infected controls; one
group of animals infected by H. pylori strain SS1; one group of
mice supplemented with 50 mM of DHA in the drinking water;
and one group infected by H. pylori strain SS1 and supplemented
with 50 mM of DHA in the drinking water as described in
materials and methods. Data from the control group and DHA
treated mice are not colonized as expected and not reported in the
figure. These four groups of animals were used during the course
of our experiment at every time-point: one, three, six and nine
months. Regardless infection status and DHA treatment, all mice
were weighted at each time-points of sacrifice. Results are
represented as percentage of control group values. t-test analysis
showed no significant differences over time amongst mice weight
with DHA treatment and with or without H. pylori infection
compared to controls. Bars represent standard deviation.
(DOCX)
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